Oragenics Cost Of Revenue vs Ebitda Analysis

Stocks . USA . 
Stock . Oragenics
OGEN Stock  USD 0.20  0.01  5.26%   
Oragenics financial indicator trend analysis is much more than just breaking down Oragenics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oragenics is a good investment. Please check the relationship between Oragenics Cost Of Revenue and its Ebitda accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oragenics Cost Of Revenue account and Ebitda. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Oragenics' Cost Of Revenue and Ebitda is -0.09. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Oragenics, assuming nothing else is changed. The correlation between historical values of Oragenics' Cost Of Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Oragenics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Cost Of Revenue i.e., Oragenics' Cost Of Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.09
Relationship DirectionNegative 
Relationship StrengthInsignificant

Cost Of Revenue

Cost of Revenue is found on Oragenics income statement and represents the costs associated with goods and services Oragenics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Ebitda

Most indicators from Oragenics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oragenics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.At this time, Oragenics' Issuance Of Capital Stock is very stable compared to the past year. As of the 27th of April 2025, Sales General And Administrative To Revenue is likely to grow to 136.83, while Selling General Administrative is likely to drop about 4.3 M.
 2024 2025 (projected)
Interest Income45.9K43.6K
Discontinued Operations27.2K25.9K

Oragenics fundamental ratios Correlations

Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Net Receivables
Short Term Debt
Current Deferred Revenue
Short Term Investments
Total Assets
-0.3-0.270.970.66-0.97-0.110.081.00.381.00.1-0.29-0.240.350.18-0.220.671.00.690.09-0.21-0.15-0.26-0.33-0.25
Other Current Liab
-0.30.59-0.41-0.130.410.3-0.42-0.32-0.24-0.32-0.22-0.240.59-0.32-0.330.57-0.13-0.3-0.17-0.190.540.710.570.59-0.25
Total Current Liabilities
-0.270.59-0.480.020.480.150.15-0.290.02-0.29-0.21-0.050.96-0.1-0.21.0-0.03-0.28-0.20.060.990.640.990.86-0.1
Total Stockholder Equity
0.97-0.41-0.480.58-1.0-0.130.030.980.330.980.13-0.26-0.440.340.21-0.430.620.980.680.07-0.42-0.28-0.47-0.5-0.21
Property Plant And Equipment Net
0.66-0.130.020.58-0.57-0.20.150.640.650.640.23-0.14-0.030.020.230.110.720.640.580.080.09-0.220.02-0.14-0.16
Net Debt
-0.970.410.48-1.0-0.570.11-0.04-0.98-0.32-0.98-0.130.260.44-0.33-0.20.43-0.59-0.97-0.71-0.040.420.260.470.490.21
Retained Earnings
-0.110.30.15-0.13-0.20.11-0.55-0.07-0.44-0.07-0.91-0.780.38-0.08-0.990.12-0.35-0.09-0.08-0.740.210.530.230.520.51
Accounts Payable
0.08-0.420.150.030.15-0.04-0.550.060.490.060.320.40.010.310.520.180.030.06-0.020.460.08-0.240.05-0.12-0.35
Cash
1.0-0.32-0.290.980.64-0.98-0.070.060.351.00.08-0.3-0.250.330.15-0.240.641.00.730.05-0.23-0.14-0.28-0.33-0.23
Non Current Assets Total
0.38-0.240.020.330.65-0.32-0.440.490.350.350.39-0.03-0.11-0.070.430.080.450.340.270.390.02-0.28-0.03-0.19-0.19
Cash And Short Term Investments
1.0-0.32-0.290.980.64-0.98-0.070.061.00.350.08-0.3-0.250.330.15-0.240.641.00.730.05-0.23-0.14-0.28-0.33-0.23
Common Stock Total Equity
0.1-0.22-0.210.130.23-0.13-0.910.320.080.390.080.79-0.44-0.220.92-0.170.390.080.230.71-0.24-0.48-0.26-0.49-0.33
Common Stock Shares Outstanding
-0.29-0.24-0.05-0.26-0.140.26-0.780.4-0.3-0.03-0.30.79-0.25-0.070.77-0.040.01-0.3-0.170.57-0.1-0.33-0.1-0.27-0.18
Non Current Liabilities Total
-0.240.590.96-0.44-0.030.440.380.01-0.25-0.11-0.25-0.44-0.25-0.02-0.420.95-0.11-0.23-0.19-0.140.970.690.980.910.0
Other Current Assets
0.35-0.32-0.10.340.02-0.33-0.080.310.33-0.070.33-0.22-0.07-0.020.1-0.09-0.10.36-0.09-0.2-0.11-0.21-0.12-0.18-0.23
Other Stockholder Equity
0.18-0.33-0.20.210.23-0.2-0.990.520.150.430.150.920.77-0.420.1-0.170.390.170.140.73-0.25-0.54-0.27-0.56-0.52
Total Liab
-0.220.571.0-0.430.110.430.120.18-0.240.08-0.24-0.17-0.040.95-0.09-0.170.03-0.22-0.150.060.990.610.980.84-0.11
Property Plant And Equipment Gross
0.67-0.13-0.030.620.72-0.59-0.350.030.640.450.640.390.01-0.11-0.10.390.030.660.530.550.03-0.24-0.01-0.17-0.15
Total Current Assets
1.0-0.3-0.280.980.64-0.97-0.090.061.00.341.00.08-0.3-0.230.360.17-0.220.660.690.07-0.22-0.14-0.26-0.32-0.25
Common Stock
0.69-0.17-0.20.680.58-0.71-0.08-0.020.730.270.730.23-0.17-0.19-0.090.14-0.150.530.690.03-0.14-0.17-0.19-0.26-0.19
Property Plant Equipment
0.09-0.190.060.070.08-0.04-0.740.460.050.390.050.710.57-0.14-0.20.730.060.550.070.030.01-0.280.01-0.18-0.23
Short Long Term Debt Total
-0.210.540.99-0.420.090.420.210.08-0.230.02-0.23-0.24-0.10.97-0.11-0.250.990.03-0.22-0.140.010.621.00.87-0.01
Net Receivables
-0.150.710.64-0.28-0.220.260.53-0.24-0.14-0.28-0.14-0.48-0.330.69-0.21-0.540.61-0.24-0.14-0.17-0.280.620.640.81-0.06
Short Term Debt
-0.260.570.99-0.470.020.470.230.05-0.28-0.03-0.28-0.26-0.10.98-0.12-0.270.98-0.01-0.26-0.190.011.00.640.890.0
Current Deferred Revenue
-0.330.590.86-0.5-0.140.490.52-0.12-0.33-0.19-0.33-0.49-0.270.91-0.18-0.560.84-0.17-0.32-0.26-0.180.870.810.890.22
Short Term Investments
-0.25-0.25-0.1-0.21-0.160.210.51-0.35-0.23-0.19-0.23-0.33-0.180.0-0.23-0.52-0.11-0.15-0.25-0.19-0.23-0.01-0.060.00.22
Click cells to compare fundamentals

Oragenics Account Relationship Matchups

High Positive Relationship

Cash
+ 1.0
Total Assets
Cash And Short Term Investments
+ 1.0
Total Assets
Total Current Assets
+ 1.0
Total Assets
Total Liab
+ 1.0
Total Current Liabilities
Cash And Short Term Investments
+ 1.0
Cash
Total Current Assets
+ 1.0
Cash

High Negative Relationship

Net Debt
- 1.0
Total Stockholder Equity
Other Stockholder Equity
- 0.99
Retained Earnings
Cash And Short Term Investments
- 0.98
Net Debt
Cash
- 0.98
Net Debt
Total Current Assets
- 0.97
Net Debt
Net Debt
- 0.97
Total Assets

Oragenics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets18.7M28.2M14.8M5.0M1.5M1.4M
Other Current Liab429.7K92.6K673.1K230.7K211.2K390.2K
Total Current Liabilities1.3M1.4M1.6M1.8M1.7M1.6M
Total Stockholder Equity16.8M26.5M13.0M3.2M(211.9K)(201.3K)
Property Plant And Equipment Net914.7K697.9K523.6K468.5K9.8K0.0
Net Debt(16.7M)(26.5M)(10.8M)(3.2M)(536.3K)(563.1K)
Retained Earnings(154.4M)(171.3M)(185.6M)(206.2M)(216.8M)(205.9M)
Accounts Payable330.4K855.0K246.7K1.2M1.1M603.0K
Cash17.6M27.3M11.4M3.5M864.8K821.6K
Non Current Assets Total914.7K697.9K523.6K468.5K1.1M0.0
Cash And Short Term Investments17.6M27.3M11.4M3.5M864.8K821.6K
Common Stock Shares Outstanding942.2K1.9M2.0M2.2M6.6M7.0M
Liabilities And Stockholders Equity18.7M28.2M14.8M5.0M1.5M1.4M
Non Current Liabilities Total952.9K670.7K493.8K299.5K152.4K0.0
Other Current Assets686.2K434.7K373.0K382.3K607.7K731.1K
Other Stockholder Equity164.0M195.0M197.0M207.8M216.6M227.4M
Total Liab1.8M1.7M1.7M1.8M1.7M1.8M
Property Plant And Equipment Gross116.3K914.7K697.9K2.2M1.8M0.0
Total Current Assets18.0M27.7M14.3M3.9M1.5M1.4M
Accumulated Other Comprehensive Income(1.6M)(1.7M)0.0(1.6M)(1.4M)(1.5M)
Common Stock91.8K116.4K2.0K3.1K12.6K11.9K
Property Plant Equipment92.0K42.7K523.6K468.5K421.7K228.1K
Short Long Term Debt Total898.9K797.2K624.5K322.5K328.5K573.1K
Short Term Debt582.0K497.7K676.5K322.5K328.5K522.7K
Net Tangible Assets10.7M9.7M23.8M11.4M13.1M9.0M
Non Currrent Assets Other(697.9K)(523.6K)(468.5K)1.1M1.3M1.3M
Short Long Term Debt228.2K303.4K267.6K328.5K377.8K396.7K
Net Invested Capital9.9M24.1M11.7M116.6K134.1K127.4K
Net Working Capital16.6M26.3M12.7M(211.9K)(190.7K)(181.2K)
Capital Stock7.3M2.8M1.6M12.6K11.3K10.7K
When determining whether Oragenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oragenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oragenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oragenics Stock:
How To Invest In Oragenics
Details
Is Oragenics Stock a good investment?
Details
What is Oragenics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.60)
Quarterly Revenue Growth
(0.91)
Return On Assets
(2.05)
Return On Equity
(7.15)
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY